Compare AGPU & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AGPU | MDXH |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | Belgium |
| Employees | 14 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 41.1M |
| IPO Year | N/A | 2021 |
| Metric | AGPU | MDXH |
|---|---|---|
| Price | $7.07 | $0.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 354.8K | ★ 730.8K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12,476.23 | $30.78 |
| Revenue Next Year | $55.17 | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.51 |
| 52 Week High | $10.86 | $5.33 |
| Indicator | AGPU | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 53.27 | 20.90 |
| Support Level | $3.66 | $0.51 |
| Resistance Level | $8.81 | $3.79 |
| Average True Range (ATR) | 1.03 | 0.07 |
| MACD | -0.13 | 0.05 |
| Stochastic Oscillator | 39.35 | 12.62 |
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.